Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial

Leuk Lymphoma. 2017 Feb;58(2):461-465. doi: 10.1080/10428194.2016.1201573. Epub 2016 Jul 7.

Authors

Alexey V Danilov¹, Hongli Li², Oliver W Press³, Ilan Shapira⁴, Lode J Swinnen⁵, Ariela Noy⁶, Erin Reid⁷, Sonali M Smith⁸, Jonathan W Friedberg⁹

Affiliations

¹ a Oregon Health & Science University , Portland , OR , USA.
² b SWOG Statistical Center , Seattle , WA , USA.
³ c Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
⁴ d Mount Sinai Beth Israel Medical Center , New York , NY , USA.
⁵ e Johns Hopkins Cancer Center , Baltimore , MD , USA.
⁶ f Memorial Sloan Kettering Cancer Center and Weill-Cornell Medical College , New York , NY , USA.
⁷ g University of California at San Diego Moores Cancer Center , La Jolla , CA , USA.
⁸ h University of Chicago , Chicago , IL , USA.
⁹ i University of Rochester , Rochester , NY , USA.

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Multicenter Study

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / adverse effects
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bleomycin / adverse effects
Bleomycin / therapeutic use
Dacarbazine / adverse effects
Dacarbazine / therapeutic use
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Female
Fluorodeoxyglucose F18
HIV Seropositivity
Hodgkin Disease* / diagnosis
Hodgkin Disease* / etiology
Hodgkin Disease* / mortality
Hodgkin Disease* / therapy
Humans
Kaplan-Meier Estimate
Male
Neoplasm Metastasis
Neoplasm Staging
Positron-Emission Tomography* / methods
Treatment Outcome
Vinblastine / adverse effects
Vinblastine / therapeutic use

Substances

Bleomycin
Dacarbazine
Doxorubicin
Fluorodeoxyglucose F18
Vinblastine

Supplementary concepts

ABVD protocol

Grants and funding